Healthcare Industry News: Dexcom
News Release - October 8, 2008
Apieron, Inc. Announces Appointment of Holly McGarraugh as President and Chief Executive Officer
MENLO PARK, Calif., Oct. 8 (Healthcare Sales & Marketing Network) -- Apieron, Inc. (www.apieron.com) announced today that its Board of Directors has appointed Holly McGarraugh as president and CEO of the company, effective immediately. Ms. McGarraugh replaces Rich Lotti, who resigned to pursue other business interests."We chose Holly for the CEO position because of her strong commercialization experience," said Wende Hutton, Apieron Board member and partner with Canaan Partners. "Holly has made a remarkable contribution to Apieron since she joined the company, and we are confident that she will add considerable value to the company, leading Apieron through commercialization in the asthma therapy marketplace."
Ms. McGarraugh, a 20-year veteran of the consumer medical device industry, joined Apieron as vice president of marketing in January 2008. She was previously vice president of worldwide marketing for in vivo products at Abbott Diabetes Care where she lead commercialization efforts, including clinical acceptance and reimbursement, for continuous glucose monitoring, a new product category. Abbott Labs formed Abbott Diabetes Care by acquiring TheraSense, a start-up where Ms. McGarraugh had been vice president of marketing and professional relations.
"Apieron recently received FDA clearance for the Insight eNO System, for which we are in the process of executing an early commercialization plan," said Holly McGarraugh, CEO of Apieron. "I am looking forward to leading a tremendously talented team focused on building relationships with the therapeutic community to improve the standard of care for people who suffer with asthma."
About Apieron Inc.
Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non-invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.
About Canaan Partners Healthcare
Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. For 20 years, the partners have taken an active and committed role in the companies in which they invest, and have completed more than 69 mergers and acquisitions and 52 IPOs. With $3 billion under management and a worldwide footprint, the firm's healthcare team is committed to catalyzing the development of biopharmaceutical, medical device, diagnostic and therapeutics companies that are revolutionizing the practice of medicine. Among recent successes are Cerexa Inc., one of the largest biotech acquisitions of 2007; Advanced BioHealing, a leader in regenerative medicine; and Dexcom Inc., the largest diagnostic IPO of 2005. Other Canaan healthcare investments include Amicus Therapeutics, Chimerix, Inc., ReVision Optics, Inc., and Transoma Medical, Inc. Canaan has offices in California, Connecticut, India and Israel. For more information, visit http://www.canaan.com.
Source: Apieron
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
